PMC:7283670 / 91203-91817 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T487","span":{"begin":45,"end":53},"obj":"Disease"},{"id":"T488","span":{"begin":277,"end":285},"obj":"Disease"},{"id":"T489","span":{"begin":429,"end":437},"obj":"Disease"}],"attributes":[{"id":"A487","pred":"mondo_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A488","pred":"mondo_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A489","pred":"mondo_id","subj":"T489","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T772","span":{"begin":232,"end":238},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T773","span":{"begin":326,"end":327},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T774","span":{"begin":348,"end":349},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T376","span":{"begin":27,"end":32},"obj":"Chemical"},{"id":"T377","span":{"begin":147,"end":156},"obj":"Chemical"},{"id":"T378","span":{"begin":167,"end":176},"obj":"Chemical"},{"id":"T379","span":{"begin":186,"end":191},"obj":"Chemical"},{"id":"T380","span":{"begin":192,"end":202},"obj":"Chemical"},{"id":"T381","span":{"begin":259,"end":264},"obj":"Chemical"},{"id":"T382","span":{"begin":287,"end":296},"obj":"Chemical"},{"id":"T383","span":{"begin":297,"end":306},"obj":"Chemical"},{"id":"T384","span":{"begin":356,"end":361},"obj":"Chemical"},{"id":"T385","span":{"begin":362,"end":372},"obj":"Chemical"},{"id":"T386","span":{"begin":413,"end":418},"obj":"Chemical"},{"id":"T387","span":{"begin":531,"end":540},"obj":"Chemical"},{"id":"T388","span":{"begin":551,"end":560},"obj":"Chemical"},{"id":"T389","span":{"begin":570,"end":575},"obj":"Chemical"},{"id":"T390","span":{"begin":576,"end":586},"obj":"Chemical"}],"attributes":[{"id":"A376","pred":"chebi_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A377","pred":"chebi_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A378","pred":"chebi_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A379","pred":"chebi_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A380","pred":"chebi_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A381","pred":"chebi_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A382","pred":"chebi_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A383","pred":"chebi_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A384","pred":"chebi_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A385","pred":"chebi_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A386","pred":"chebi_id","subj":"T386","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A387","pred":"chebi_id","subj":"T387","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A388","pred":"chebi_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A389","pred":"chebi_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A390","pred":"chebi_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"}],"text":"Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days"}

{"project":"LitCovid-sentences","denotations":[{"id":"T784","span":{"begin":55,"end":231},"obj":"Sentence"},{"id":"T785","span":{"begin":232,"end":286},"obj":"Sentence"},{"id":"T786","span":{"begin":287,"end":385},"obj":"Sentence"},{"id":"T787","span":{"begin":386,"end":438},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1863","span":{"begin":186,"end":225},"obj":"Gene"},{"id":"1864","span":{"begin":570,"end":609},"obj":"Gene"},{"id":"2082","span":{"begin":147,"end":156},"obj":"Chemical"},{"id":"2083","span":{"begin":287,"end":306},"obj":"Chemical"},{"id":"2084","span":{"begin":531,"end":540},"obj":"Chemical"}],"attributes":[{"id":"A2082","pred":"tao:has_database_id","subj":"2082","obj":"MESH:D061466"},{"id":"A2083","pred":"tao:has_database_id","subj":"2083","obj":"MESH:C558899"},{"id":"A2084","pred":"tao:has_database_id","subj":"2084","obj":"MESH:D061466"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days"}